Synaptic Pharmaceutical Corporation

H. Lundbeck A/s

Mary W Walker

Theresa A Branchek

Richard L Weinshank

Christophe P Gerald

Christophe P G Gerald

Jonathan A Bard

Kenneth A Jones

Joseph Tamm

This invention provides isolated nucleic acids encoding chimeric G proteins, vectors comprising nucleic acids encoding chimeric G proteins, cells comprising such vectors, processes of determining agonists and antagonists of mammalian G protein-coupled receptors utilizing chimeric G proteins, processes of determining compounds which bind to mammalian G protein-coupled receptors utilizing chimeric G proteins, processes for making a composition of matter which specifically binds to a mammalian G protein-coupled receptor utilizing chimeric G proteins, processes for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by a process of the invention utilizing chimeric G proteins, processes of identifying a ligand for a mammalian G protein-coupled receptor utilizing chimeric G proteins, and processes of screening a plurality of independent clones to identify and isolate a clone encoding a mammalian G protein-coupled receptor utilizing chimeric G proteins.

Chimeric G proteins and uses thereof

This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Method of obtaining compositions comprising Y4 specific compounds

This invention provides isolated nucleic acid molecules encoding a neuropeptide Y (NPY) Y5 receptor which hybridizes under high stringency conditions to a nucleic acid molecule of SEQ ID NO:3, vectors comprising such isolated nucleic acid molecules, and cells comprising such vectors.

Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

The invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has structure (I). In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

Methods of modifying feeding behavior using compounds with afinity for the human hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.

Method of obtaining compositions comprising Y2 specific compounds

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure:

Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

Methods of modifying feeding behavior compounds useful in such methods

Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors

DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide

This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor

This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Processes for identifying compounds that bind to the human Y4 receptor

This invention provides an isolated nucleic acid molecule encoding a human Y5 receptor, an isolated protein which is a human Y5 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y5 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y5 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y5 receptor, pharmaceutical compounds related to human Y5 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y5 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y5 receptor.

This invention provides an isolated nucleic acid molecule encoding a human Y2 receptor, an isolated protein which is a human Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y2 receptor, pharmaceutical compounds related to human Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y2 receptor.

Growing community of inventors

Elmwood Park, NJ, United States of America

Mary W Walker